Trastuzumab emtansine [Kadcyla]
Sponsors
Genentech, Inc., Hoffmann-La Roche
Conditions
Breast CancerMetastatic Breast Cancer
Phase 1
Phase 2
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
CompletedNCT00509769
Start: 2007-07-31End: 2009-06-30Updated: 2013-04-02
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
CompletedNCT00679341
Start: 2008-09-30End: 2012-05-31Updated: 2014-01-09
A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
CompletedNCT00679211
Start: 2008-08-31End: 2011-04-30Updated: 2017-03-31
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
CompletedNCT00943670
Start: 2009-07-31End: 2011-08-31Updated: 2013-05-27